Aditxt Inc (ADTX) Actualités

Form DEF 14A - Other definitive proxy statements

Form PRER14A - Preliminary Proxy Soliciting materials

Form 8-K - Current report

Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, is...

Form 8-K - Current report

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Submission for Regulatory Approval to Initiate Human Trials for Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome Targeted for H2 2025...

Form PRE 14A - Other preliminary proxy statements

Form 8-K/A - Current report: [Amend]

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 PR Newswire SAN DIEGO, Nov. 14...

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek...